Regeneron Pharmaceuticals Inc. (REGN) Nasdaq Global Select
418.841.460.35%
CloseJanuary 18, 2019

News: updated – 21-Jan 06:27


Regeneron Likely To Outperform In 201918-Jan 05:14(SeekingAlpha)

Regeneron ( REGN ) is a biotechnology company with a focus on helping patients with eye diseases, allergic & inflammatory conditions, cancer, and neuromuscular diseases. The company will report earnings on February 24, 2019, and I believe a strong report and possible Spring approvals will …

Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 201918-Jan 04:01(PR Newswire)

TARRYTOWN, N.Y. , Jan. 18, 2019 /PRNewswire/ –Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its fourth quarter and full year 2018 financial and operating results on Wednesday, February 6, 2019 , before the U.S. financial markets open. &#xA…

The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks18-Jan 09:27(SeekingAlpha)

There were numerous highlights in the healthcare sector beginning 2019. First, the announced merger of Bristol Myers ( BMY ) and Celgene ( CELG ) will create a strong entity in oncology and hematology, and will be very accretive to Bristol’s earnings per share. Wall Street had driven down Celg…